{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T03:14:05Z","timestamp":1794021245547,"version":"4.8.0"},"reference-count":72,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T00:00:00Z","timestamp":1739318400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T00:00:00Z","timestamp":1739318400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AAPS J"],"DOI":"10.1208\/s12248-025-01031-y","type":"journal-article","created":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T21:28:01Z","timestamp":1739395681000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Application of a Physiologically Based Pharmacokinetic Approach to Predict Tenofovir Pharmacokinetics During Pregnancy"],"prefix":"10.1208","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0725-9237","authenticated-orcid":false,"given":"Khaled","family":"Abduljalil","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mailys","family":"De Sousa Mendes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farzaneh","family":"Salem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sihem","family":"Benaboud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iain","family":"Gardner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,12]]},"reference":[{"issue":"6","key":"1031_CR1","doi-asserted-by":"publisher","first-page":"365","DOI":"10.2165\/11597440-000000000-00000","volume":"51","author":"K Abduljalil","year":"2012","unstructured":"Abduljalil K, Furness P, Johnson TN, Rostami-Hodjegan A, Soltani H. Anatomical, physiological and metabolic changes with gestational age during normal pregnancy: a database for parameters required in physiologically based pharmacokinetic modelling. Clin Pharmacokinet. 2012;51(6):365\u201396. https:\/\/doi.org\/10.2165\/11597440-000000000-00000.","journal-title":"Clin Pharmacokinet"},{"key":"1031_CR2","doi-asserted-by":"publisher","DOI":"10.1007\/s10928-020-09698-w","author":"K Abduljalil","year":"2020","unstructured":"Abduljalil K, Badhan RKS. Drug dosing during pregnancy-opportunities for physiologically based pharmacokinetic models. J Pharmacokinet Pharmacodyn. 2020. https:\/\/doi.org\/10.1007\/s10928-020-09698-w.","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"1031_CR3","unstructured":"Panel on Treatment of HIV During Pregnancy and Prevention of Perinatal Transmission. Recommendations for the Use of Antiretroviral Drugs During Pregnancy and Interventions to Reduce Perinatal HIV Transmission in the United States. Department of Health and Human Services. 2004. Available at https:\/\/clinicalinfo.hiv.gov\/en\/guidelines\/perinatal. Accessed 23 Apr 2024."},{"issue":"6","key":"1031_CR4","doi-asserted-by":"publisher","first-page":"2367","DOI":"10.1128\/AAC.01523-08","volume":"53","author":"RF Yeh","year":"2009","unstructured":"Yeh RF, Rezk NL, Kashuba AD, Dumond JB, Tappouni HL, Tien HC, et al. Genital tract, cord blood, and amniotic fluid exposures of seven antiretroviral drugs during and after pregnancy in human immunodeficiency virus type 1-infected women. Antimicrob Agents Chemother. 2009;53(6):2367\u201374. https:\/\/doi.org\/10.1128\/AAC.01523-08.","journal-title":"Antimicrob Agents Chemother"},{"key":"1031_CR5","doi-asserted-by":"publisher","first-page":"232595822091923","DOI":"10.1177\/2325958220919231","volume":"19","author":"C Wassner","year":"2020","unstructured":"Wassner C, Bradley N, Lee Y. A Review and Clinical Understanding of Tenofovir: Tenofovir Disoproxil Fumarate versus Tenofovir Alafenamide. J Int Assoc Provid AIDS Care. 2020;19:2325958220919231. https:\/\/doi.org\/10.1177\/2325958220919231.","journal-title":"J Int Assoc Provid AIDS Care"},{"issue":"4","key":"1031_CR6","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1002\/cpt.1464","volume":"106","author":"SA Greene","year":"2019","unstructured":"Greene SA, Chen J, Prince HMA, Sykes C, Schauer AP, Blake K, et al. Population Modeling Highlights Drug Disposition Differences Between Tenofovir Alafenamide and Tenofovir Disoproxil Fumarate in the Blood and Semen. Clin Pharmacol Ther. 2019;106(4):821\u201330. https:\/\/doi.org\/10.1002\/cpt.1464.","journal-title":"Clin Pharmacol Ther"},{"issue":"9","key":"1031_CR7","doi-asserted-by":"publisher","first-page":"595","DOI":"10.2165\/00003088-200443090-00003","volume":"43","author":"BP Kearney","year":"2004","unstructured":"Kearney BP, Flaherty JF, Shah J. Tenofovir disoproxil fumarate: clinical pharmacology and pharmacokinetics. Clin Pharmacokinet. 2004;43(9):595\u2013612. https:\/\/doi.org\/10.2165\/00003088-200443090-00003.","journal-title":"Clin Pharmacokinet"},{"key":"1031_CR8","doi-asserted-by":"publisher","first-page":"104815","DOI":"10.1016\/j.antiviral.2020.104815","volume":"179","author":"C Pierra Rouviere","year":"2020","unstructured":"Pierra Rouviere C, Dousson CB, Tavis JE. HBV replication inhibitors. Antiviral Res. 2020;179:104815. https:\/\/doi.org\/10.1016\/j.antiviral.2020.104815.","journal-title":"Antiviral Res"},{"issue":"1","key":"1031_CR9","first-page":"6","volume":"4","author":"MA Thimm","year":"2022","unstructured":"Thimm MA, Livingston A, Ramroop R, Eke AC. Pregnancy Outcomes in Pregnant Women with HIV on Tenofovir Disoproxil Fumarate (TDF) Compared to Tenofovir Alafenamide (TAF). J AIDS HIV Treat. 2022;4(1):6\u201313.","journal-title":"J AIDS HIV Treat"},{"issue":"8","key":"1031_CR10","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1097\/INF.0b013e3181e74a2f","volume":"29","author":"SB Brogly","year":"2010","unstructured":"Brogly SB, Abzug MJ, Watts DH, Cunningham CK, Williams PL, Oleske J, et al. Birth defects among children born to human immunodeficiency virus-infected women: pediatric AIDS clinical trials protocols 219 and 219C. Pediatr Infect Dis J. 2010;29(8):721\u20137. https:\/\/doi.org\/10.1097\/INF.0b013e3181e74a2f.","journal-title":"Pediatr Infect Dis J"},{"issue":"4","key":"1031_CR11","doi-asserted-by":"publisher","first-page":"e1001635","DOI":"10.1371\/journal.pmed.1001635","volume":"11","author":"J Sibiude","year":"2014","unstructured":"Sibiude J, Mandelbrot L, Blanche S, Le Chenadec J, Boullag-Bonnet N, Faye A, et al. Association between prenatal exposure to antiretroviral therapy and birth defects: an analysis of the French perinatal cohort study (ANRS CO1\/CO11). PLoS Med. 2014;11(4):e1001635. https:\/\/doi.org\/10.1371\/journal.pmed.1001635.","journal-title":"PLoS Med"},{"issue":"1","key":"1031_CR12","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1001\/jamapediatrics.2014.1889","volume":"169","author":"PL Williams","year":"2015","unstructured":"Williams PL, Crain MJ, Yildirim C, Hazra R, Van Dyke RB, Rich K, et al. Congenital anomalies and in utero antiretroviral exposure in human immunodeficiency virus-exposed uninfected infants. JAMA Pediatr. 2015;169(1):48\u201355. https:\/\/doi.org\/10.1001\/jamapediatrics.2014.1889.","journal-title":"JAMA Pediatr"},{"issue":"18","key":"1031_CR13","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1056\/NEJMoa1511691","volume":"375","author":"MG Fowler","year":"2016","unstructured":"Fowler MG, Qin M, Fiscus SA, Currier JS, Flynn PM, Chipato T, et al. Benefits and risks of antiretroviral therapy for perinatal HIV prevention. N Engl J Med. 2016;375(18):1726\u201337. https:\/\/doi.org\/10.1056\/NEJMoa1511691.","journal-title":"N Engl J Med"},{"issue":"5","key":"1031_CR14","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1097\/QAI.0000000000002072","volume":"81","author":"D Sebikari","year":"2019","unstructured":"Sebikari D, Farhad M, Fenton T, Owor M, Stringer JSA, Qin M, et al. Risk factors for adverse birth outcomes in the PROMISE 1077BF\/1077FF trial. J Acquir Immune Defic Syndr. 2019;81(5):521\u201332. https:\/\/doi.org\/10.1097\/QAI.0000000000002072.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"17","key":"1031_CR15","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1056\/NEJMoa1701666","volume":"378","author":"K Rough","year":"2018","unstructured":"Rough K, Seage GR 3rd, Williams PL, Hernandez-Diaz S, Huo Y, Chadwick EG, et al. Birth outcomes for pregnant women with HIV using tenofovir-emtricitabine. N Engl J Med. 2018;378(17):1593\u2013603. https:\/\/doi.org\/10.1056\/NEJMoa1701666.","journal-title":"N Engl J Med"},{"issue":"10","key":"1031_CR16","doi-asserted-by":"publisher","first-page":"e172222","DOI":"10.1001\/jamapediatrics.2017.2222","volume":"171","author":"R Zash","year":"2017","unstructured":"Zash R, Jacobson DL, Diseko M, Mayondi G, Mmalane M, Essex M, et al. Comparative safety of antiretroviral treatment regimens in pregnancy. JAMA Pediatr. 2017;171(10):e172222. https:\/\/doi.org\/10.1001\/jamapediatrics.2017.2222.","journal-title":"JAMA Pediatr"},{"issue":"3","key":"1031_CR17","doi-asserted-by":"publisher","first-page":"e148","DOI":"10.1093\/jpids\/piy006","volume":"7","author":"R Zash","year":"2018","unstructured":"Zash R, Rough K, Jacobson DL, Diseko M, Mayondi G, Mmalane M, et al. Effect of gestational age at tenofovir-emtricitabine-efavirenz initiation on adverse birth outcomes in Botswana. J Pediatric Infect Dis Soc. 2018;7(3):e148\u201351. https:\/\/doi.org\/10.1093\/jpids\/piy006.","journal-title":"J Pediatric Infect Dis Soc"},{"issue":"9","key":"1031_CR18","doi-asserted-by":"publisher","first-page":"2380","DOI":"10.1128\/AAC.42.9.2380","volume":"42","author":"SG Deeks","year":"1998","unstructured":"Deeks SG, Barditch-Crovo P, Lietman PS, Hwang F, Cundy KC, Rooney JF, et al. Safety, pharmacokinetics, and antiretroviral activity of intravenous 9-[2-(R)-(Phosphonomethoxy)propyl]adenine, a novel anti-human immunodeficiency virus (HIV) therapy, in HIV-infected adults. Antimicrob Agents Chemother. 1998;42(9):2380\u20134. https:\/\/doi.org\/10.1128\/AAC.42.9.2380.","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"1031_CR19","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1002\/cpt.1714","volume":"107","author":"SN Liu","year":"2020","unstructured":"Liu SN, Gufford BT, Lu JBL, Bushman LR, Anderson PL, Bergstrom RF, et al. Inhibitory effects of probenecid on pharmacokinetics of tenofovir disoproxil fumarate and emtricitabine for on-demand HIV preexposure prophylaxis. Clin Pharmacol Ther. 2020;107(5):1200\u20138. https:\/\/doi.org\/10.1002\/cpt.1714.","journal-title":"Clin Pharmacol Ther"},{"issue":"8","key":"1031_CR20","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1111\/hiv.12252","volume":"16","author":"BM Best","year":"2015","unstructured":"Best BM, Burchett S, Li H, Stek A, Hu C, Wang J, et al. Pharmacokinetics of tenofovir during pregnancy and postpartum. HIV Med. 2015;16(8):502\u201311. https:\/\/doi.org\/10.1111\/hiv.12252.","journal-title":"HIV Med"},{"issue":"5","key":"1031_CR21","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1097\/QAD.0b013e32835c208b","volume":"27","author":"AP Colbers","year":"2013","unstructured":"Colbers AP, Hawkins DA, Gingelmaier A, Kabeya K, Rockstroh JK, Wyen C, et al. The pharmacokinetics, safety and efficacy of tenofovir and emtricitabine in HIV-1-infected pregnant women. AIDS. 2013;27(5):739\u201348. https:\/\/doi.org\/10.1097\/QAD.0b013e32835c208b.","journal-title":"AIDS"},{"key":"1031_CR22","doi-asserted-by":"publisher","unstructured":"Cressey TR, Harrison L, Achalapong J, Kanjanavikai P, Patamasingh Na Ayudhaya O, Liampongsabuddhi P, et al. Tenofovir Exposure during Pregnancy and Postpartum in Women Receiving Tenofovir Disoproxil Fumarate for the Prevention of Mother-to-Child Transmission of Hepatitis B Virus. Antimicrob Agents Chemother. 2018;62(12). https:\/\/doi.org\/10.1128\/AAC.01686-18.","DOI":"10.1128\/AAC.01686-18"},{"issue":"4","key":"1031_CR23","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1002\/bdd.2257","volume":"42","author":"E El-Khateeb","year":"2021","unstructured":"El-Khateeb E, Burkhill S, Murby S, Amirat H, Rostami-Hodjegan A, Ahmad A. Physiological-based pharmacokinetic modeling trends in pharmaceutical drug development over the last 20-years; in-depth analysis of applications, organizations, and platforms. Biopharm Drug Dispos. 2021;42(4):107\u201317. https:\/\/doi.org\/10.1002\/bdd.2257.","journal-title":"Biopharm Drug Dispos"},{"key":"1031_CR24","doi-asserted-by":"publisher","first-page":"1403747","DOI":"10.3389\/fphar.2024.1403747","volume":"15","author":"CJM Koldeweij","year":"2024","unstructured":"Koldeweij CJM, Dibbets AC, Ceulemans M, de Vries LC, Franklin BD, Scheepers HCJ, et al. Willingness-to-use and preferences for model-informed antenatal doses: a cross-sectional study among European healthcare practitioners and pregnant women. Front Pharmacol. 2024;15:1403747. https:\/\/doi.org\/10.3389\/fphar.2024.1403747.","journal-title":"Front Pharmacol"},{"issue":"1","key":"1031_CR25","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.dmpk.2016.09.004","volume":"32","author":"T Furihata","year":"2017","unstructured":"Furihata T, Morio H, Zhu M, Suzuki Y, Ide H, Tsubota A, et al. Human organic anion transporter 2 is an entecavir, but not tenofovir, transporter. Drug Metab Pharmacokinet. 2017;32(1):116\u20139. https:\/\/doi.org\/10.1016\/j.dmpk.2016.09.004.","journal-title":"Drug Metab Pharmacokinet"},{"issue":"4","key":"1031_CR26","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1124\/dmd.116.074294","volume":"45","author":"S Mathialagan","year":"2017","unstructured":"Mathialagan S, Piotrowski MA, Tess DA, Feng B, Litchfield J, Varma MV. Quantitative prediction of human renal clearance and drug-drug interactions of organic anion transporter substrates using in vitro transport data: a relative activity factor approach. Drug Metab Dispos. 2017;45(4):409\u201317. https:\/\/doi.org\/10.1124\/dmd.116.074294.","journal-title":"Drug Metab Dispos"},{"issue":"10","key":"1031_CR27","doi-asserted-by":"publisher","first-page":"3498","DOI":"10.1128\/AAC.00671-07","volume":"51","author":"L Tong","year":"2007","unstructured":"Tong L, Phan TK, Robinson KL, Babusis D, Strab R, Bhoopathy S, et al. Effects of human immunodeficiency virus protease inhibitors on the intestinal absorption of tenofovir disoproxil fumarate in vitro. Antimicrob Agents Chemother. 2007;51(10):3498\u2013504. https:\/\/doi.org\/10.1128\/AAC.00671-07.","journal-title":"Antimicrob Agents Chemother"},{"issue":"1\u20132","key":"1031_CR28","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.ijpharm.2015.03.002","volume":"485","author":"S Geboers","year":"2015","unstructured":"Geboers S, Haenen S, Mols R, Brouwers J, Tack J, Annaert P, et al. Intestinal behavior of the ester prodrug tenofovir DF in humans. Int J Pharm. 2015;485(1\u20132):131\u20137. https:\/\/doi.org\/10.1016\/j.ijpharm.2015.03.002.","journal-title":"Int J Pharm"},{"issue":"2","key":"1031_CR29","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1128\/AAC.05244-11","volume":"56","author":"S Benaboud","year":"2012","unstructured":"Benaboud S, Hirt D, Launay O, Pannier E, Firtion G, Rey E, et al. Pregnancy-related effects on tenofovir pharmacokinetics: a population study with 186 women. Antimicrob Agents Chemother. 2012;56(2):857\u201362. https:\/\/doi.org\/10.1128\/AAC.05244-11.","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"1031_CR30","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1208\/s12248-009-9099-y","volume":"11","author":"M Jamei","year":"2009","unstructured":"Jamei M, Turner D, Yang J, Neuhoff S, Polak S, Rostami-Hodjegan A, et al. Population-based mechanistic prediction of oral drug absorption. AAPS J. 2009;11(2):225\u201337. https:\/\/doi.org\/10.1208\/s12248-009-9099-y.","journal-title":"AAPS J"},{"issue":"12","key":"1031_CR31","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1002\/psp4.12717","volume":"10","author":"X Pan","year":"2021","unstructured":"Pan X, Yamazaki S, Neuhoff S, Zhang M, Pilla RV. Unraveling pleiotropic effects of rifampicin by using physiologically based pharmacokinetic modeling: Assessing the induction magnitude of P-glycoprotein-cytochrome P450 3A4 dual substrates. CPT Pharmacometrics Syst Pharmacol. 2021;10(12):1485\u201396. https:\/\/doi.org\/10.1002\/psp4.12717.","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"6","key":"1031_CR32","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1177\/0091270007300951","volume":"47","author":"MR Blum","year":"2007","unstructured":"Blum MR, Chittick GE, Begley JA, Zong J. Steady-state pharmacokinetics of emtricitabine and tenofovir disoproxil fumarate administered alone and in combination in healthy volunteers. J Clin Pharmacol. 2007;47(6):751\u20139. https:\/\/doi.org\/10.1177\/0091270007300951.","journal-title":"J Clin Pharmacol"},{"issue":"6","key":"1031_CR33","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1002\/jps.20502","volume":"95","author":"T Rodgers","year":"2006","unstructured":"Rodgers T, Rowland M. Physiologically based pharmacokinetic modelling 2: predicting the tissue distribution of acids, very weak bases, neutrals and zwitterions. J Pharm Sci. 2006;95(6):1238\u201357. https:\/\/doi.org\/10.1002\/jps.20502.","journal-title":"J Pharm Sci"},{"issue":"1","key":"1031_CR34","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/s40262-013-0097-y","volume":"53","author":"M Jamei","year":"2014","unstructured":"Jamei M, Bajot F, Neuhoff S, Barter Z, Yang J, Rostami-Hodjegan A, et al. A mechanistic framework for in vitro-in vivo extrapolation of liver membrane transporters: prediction of drug-drug interaction between rosuvastatin and cyclosporine. Clin Pharmacokinet. 2014;53(1):73\u201387. https:\/\/doi.org\/10.1007\/s40262-013-0097-y.","journal-title":"Clin Pharmacokinet"},{"key":"1031_CR35","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/978-1-4614-8229-1_7","volume-title":"Transporters in Drug Development: Discovery, Optimization, Clinical Study and Regulation","author":"S Neuhoff","year":"2013","unstructured":"Neuhoff S, Gaohua L, Burt H, Jamei M, Li L, Tucker GT, et al. Accounting for transporters in renal clearance: towards a Mechanistic Kidney Model (Mech KiM). In: Sugiyama Y, Steffansen B, editors., et al., Transporters in Drug Development: Discovery, Optimization, Clinical Study and Regulation. Springer, New York: New York; 2013. p. 155\u201377."},{"issue":"2","key":"1031_CR36","doi-asserted-by":"publisher","first-page":"326","DOI":"10.3390\/pharmaceutics3020326","volume":"3","author":"O Janneh","year":"2011","unstructured":"Janneh O, Khoo SH. Interactions of tenofovir, Lamivudine, abacavir and Didanosine in primary human cells. Pharmaceutics. 2011;3(2):326\u201337. https:\/\/doi.org\/10.3390\/pharmaceutics3020326.","journal-title":"Pharmaceutics"},{"issue":"5","key":"1031_CR37","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1093\/chromsci\/47.5.365","volume":"47","author":"Z Kuklenyik","year":"2009","unstructured":"Kuklenyik Z, Martin A, Pau CP, Garcia-Lerma JG, Heneine W, Pirkle JL, et al. Effect of mobile phase pH and organic content on LC-MS analysis of nucleoside and nucleotide HIV reverse transcriptase inhibitors. J Chromatogr Sci. 2009;47(5):365\u201372. https:\/\/doi.org\/10.1093\/chromsci\/47.5.365.","journal-title":"J Chromatogr Sci"},{"issue":"5","key":"1031_CR38","doi-asserted-by":"publisher","first-page":"1898","DOI":"10.1128\/AAC.49.5.1898-1906.2005","volume":"49","author":"WA Lee","year":"2005","unstructured":"Lee WA, He GX, Eisenberg E, Cihlar T, Swaminathan S, Mulato A, et al. Selective intracellular activation of a novel prodrug of the human immunodeficiency virus reverse transcriptase inhibitor tenofovir leads to preferential distribution and accumulation in lymphatic tissue. Antimicrob Agents Chemother. 2005;49(5):1898\u2013906. https:\/\/doi.org\/10.1128\/AAC.49.5.1898-1906.2005.","journal-title":"Antimicrob Agents Chemother"},{"key":"1031_CR39","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.saa.2014.10.070","volume":"138","author":"N Shahabadi","year":"2015","unstructured":"Shahabadi N, Hadidi S, Feizi F. Study on the interaction of antiviral drug \u201cTenofovir\u201d with human serum albumin by spectral and molecular modeling methods. Spectrochim Acta A Mol Biomol Spectrosc. 2015;138:169\u201375. https:\/\/doi.org\/10.1016\/j.saa.2014.10.070.","journal-title":"Spectrochim Acta A Mol Biomol Spectrosc"},{"issue":"10","key":"1031_CR40","doi-asserted-by":"publisher","first-page":"4905","DOI":"10.1128\/AAC.00120-11","volume":"55","author":"V de Lastours","year":"2011","unstructured":"de Lastours V, Fonsart J, Burlacu R, Gourmel B, Molina JM. Concentrations of tenofovir and emtricitabine in saliva: implications for preexposure prophylaxis of oral HIV acquisition. Antimicrob Agents Chemother. 2011;55(10):4905\u20137. https:\/\/doi.org\/10.1128\/AAC.00120-11.","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"1031_CR41","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1002\/jcph.210","volume":"54","author":"JM Custodio","year":"2014","unstructured":"Custodio JM, Yin X, Hepner M, Ling KH, Cheng A, Kearney BP, et al. Effect of food on rilpivirine\/emtricitabine\/tenofovir disoproxil fumarate, an antiretroviral single-tablet regimen for the treatment of HIV infection. J Clin Pharmacol. 2014;54(4):378\u201385. https:\/\/doi.org\/10.1002\/jcph.210.","journal-title":"J Clin Pharmacol"},{"issue":"5","key":"1031_CR42","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1007\/s11095-006-9210-3","volume":"24","author":"T Rodgers","year":"2007","unstructured":"Rodgers T, Rowland M. Mechanistic approaches to volume of distribution predictions: understanding the processes. Pharm Res. 2007;24(5):918\u201333. https:\/\/doi.org\/10.1007\/s11095-006-9210-3.","journal-title":"Pharm Res"},{"issue":"2","key":"1031_CR43","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1124\/mol.106.028233","volume":"71","author":"T Imaoka","year":"2007","unstructured":"Imaoka T, Kusuhara H, Adachi M, Schuetz JD, Takeuchi K, Sugiyama Y. Functional involvement of multidrug resistance-associated protein 4 (MRP4\/ABCC4) in the renal elimination of the antiviral drugs adefovir and tenofovir. Mol Pharmacol. 2007;71(2):619\u201327. https:\/\/doi.org\/10.1124\/mol.106.028233.","journal-title":"Mol Pharmacol"},{"issue":"4","key":"1031_CR44","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1111\/bcp.12815","volume":"81","author":"MM De Sousa","year":"2016","unstructured":"De Sousa MM, Hirt D, Vinot C, Valade E, Lui G, Pressiat C, et al. Prediction of human fetal pharmacokinetics using ex vivo human placenta perfusion studies and physiologically based models. Br J Clin Pharmacol. 2016;81(4):646\u201357. https:\/\/doi.org\/10.1111\/bcp.12815.","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"1031_CR45","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/s40262-018-0685-y","volume":"58","author":"K Abduljalil","year":"2019","unstructured":"Abduljalil K, Jamei M, Johnson TN. Fetal physiologically based pharmacokinetic models: systems information on the growth and composition of fetal organs. Clin Pharmacokinet. 2019;58(2):235\u201362. https:\/\/doi.org\/10.1007\/s40262-018-0685-y.","journal-title":"Clin Pharmacokinet"},{"issue":"5","key":"1031_CR46","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1007\/s40262-019-00836-3","volume":"59","author":"K Abduljalil","year":"2020","unstructured":"Abduljalil K, Jamei M, Johnson TN. Fetal physiologically based pharmacokinetic models: systems information on fetal blood components and binding proteins. Clin Pharmacokinet. 2020;59(5):629\u201342. https:\/\/doi.org\/10.1007\/s40262-019-00836-3.","journal-title":"Clin Pharmacokinet"},{"issue":"9","key":"1031_CR47","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1007\/s40262-017-0618-1","volume":"57","author":"K Abduljalil","year":"2018","unstructured":"Abduljalil K, Johnson TN, Rostami-Hodjegan A. Fetal physiologically-based pharmacokinetic models: systems information on fetal biometry and gross composition. Clin Pharmacokinet. 2018;57(9):1149\u201371. https:\/\/doi.org\/10.1007\/s40262-017-0618-1.","journal-title":"Clin Pharmacokinet"},{"issue":"6","key":"1031_CR48","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1007\/s40262-020-00973-0","volume":"60","author":"K Abduljalil","year":"2021","unstructured":"Abduljalil K, Pan X, Clayton R, Johnson TN, Jamei M. Fetal physiologically based pharmacokinetic models: systems information on fetal cardiac output and its distribution to different organs during development. Clin Pharmacokinet. 2021;60(6):741\u201357. https:\/\/doi.org\/10.1007\/s40262-020-00973-0.","journal-title":"Clin Pharmacokinet"},{"issue":"5","key":"1031_CR49","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1111\/j.1365-2125.2012.04363.x","volume":"74","author":"L Gaohua","year":"2012","unstructured":"Gaohua L, Abduljalil K, Jamei M, Johnson TN, Rostami-Hodjegan A. A pregnancy physiologically based pharmacokinetic (p-PBPK) model for disposition of drugs metabolized by CYP1A2, CYP2D6 and CYP3A4. Br J Clin Pharmacol. 2012;74(5):873\u201385. https:\/\/doi.org\/10.1111\/j.1365-2125.2012.04363.x.","journal-title":"Br J Clin Pharmacol"},{"key":"1031_CR50","doi-asserted-by":"publisher","unstructured":"Alrammaal HH, Abduljalil K, Hodgetts Morton V, Morris RK, Marriott JF, Chong HP, et al. Application of a physiologically based pharmacokinetic model to predict cefazolin and cefuroxime disposition in obese pregnant women undergoing caesarean section. Pharmaceutics. 2022;14(6). https:\/\/doi.org\/10.3390\/pharmaceutics14061162.","DOI":"10.3390\/pharmaceutics14061162"},{"issue":"10","key":"1031_CR51","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1124\/dmd.121.000557","volume":"49","author":"J Peng","year":"2021","unstructured":"Peng J, Ladumor MK, Unadkat JD. Prediction of pregnancy-induced changes in secretory and total renal clearance of drugs transported by organic anion transporters. Drug Metab Dispos. 2021;49(10):929\u201337. https:\/\/doi.org\/10.1124\/dmd.121.000557.","journal-title":"Drug Metab Dispos"},{"issue":"5","key":"1031_CR52","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1007\/s40262-021-01103-0","volume":"61","author":"K Abduljalil","year":"2022","unstructured":"Abduljalil K, Pansari A, Ning J, Jamei M. Prediction of maternal and fetal acyclovir, emtricitabine, lamivudine, and metformin concentrations during pregnancy using a physiologically based pharmacokinetic modeling approach. Clin Pharmacokinet. 2022;61(5):725\u201348. https:\/\/doi.org\/10.1007\/s40262-021-01103-0.","journal-title":"Clin Pharmacokinet"},{"key":"1031_CR53","doi-asserted-by":"publisher","first-page":"840710","DOI":"10.3389\/fped.2022.840710","volume":"10","author":"K Abduljalil","year":"2022","unstructured":"Abduljalil K, Gardner I, Jamei M. Application of a physiologically based pharmacokinetic approach to predict theophylline pharmacokinetics using virtual non-pregnant, pregnant, fetal, breast-feeding, and neonatal populations. Front Pediatr. 2022;10:840710. https:\/\/doi.org\/10.3389\/fped.2022.840710.","journal-title":"Front Pediatr"},{"issue":"6","key":"1031_CR54","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1002\/jcph.461","volume":"55","author":"RN Burns","year":"2015","unstructured":"Burns RN, Hendrix CW, Chaturvedula A. Population pharmacokinetics of tenofovir and tenofovir-diphosphate in healthy women. J Clin Pharmacol. 2015;55(6):629\u201338. https:\/\/doi.org\/10.1002\/jcph.461.","journal-title":"J Clin Pharmacol"},{"issue":"2","key":"1031_CR55","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1038\/clpt.2008.201","volume":"85","author":"D Hirt","year":"2009","unstructured":"Hirt D, Urien S, Ekouevi DK, Rey E, Arrive E, Blanche S, et al. Population pharmacokinetics of tenofovir in HIV-1-infected pregnant women and their neonates (ANRS 12109). Clin Pharmacol Ther. 2009;85(2):182\u20139. https:\/\/doi.org\/10.1038\/clpt.2008.201.","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"1031_CR56","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1097\/QAI.0b013e3182a921eb","volume":"65","author":"M Mirochnick","year":"2014","unstructured":"Mirochnick M, Taha T, Kreitchmann R, Nielsen-Saines K, Kumwenda N, Joao E, et al. Pharmacokinetics and safety of tenofovir in HIV-infected women during labor and their infants during the first week of life. J Acquir Immune Defic Syndr. 2014;65(1):33\u201341. https:\/\/doi.org\/10.1097\/QAI.0b013e3182a921eb.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"11","key":"1031_CR57","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.2165\/00003088-200645110-00005","volume":"45","author":"BP Kearney","year":"2006","unstructured":"Kearney BP, Yale K, Shah J, Zhong L, Flaherty JF. Pharmacokinetics and dosing recommendations of tenofovir disoproxil fumarate in hepatic or renal impairment. Clin Pharmacokinet. 2006;45(11):1115\u201324. https:\/\/doi.org\/10.2165\/00003088-200645110-00005.","journal-title":"Clin Pharmacokinet"},{"issue":"4","key":"1031_CR58","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1128\/AAC.50.4.1304-1310.2006","volume":"50","author":"GE Chittick","year":"2006","unstructured":"Chittick GE, Zong J, Blum MR, Sorbel JJ, Begley JA, Adda N, et al. Pharmacokinetics of tenofovir disoproxil fumarate and ritonavir-boosted saquinavir mesylate administered alone or in combination at steady state. Antimicrob Agents Chemother. 2006;50(4):1304\u201310. https:\/\/doi.org\/10.1128\/AAC.50.4.1304-1310.2006.","journal-title":"Antimicrob Agents Chemother"},{"issue":"9","key":"1031_CR59","doi-asserted-by":"publisher","first-page":"3253","DOI":"10.1128\/AAC.00005-08","volume":"52","author":"LA Wenning","year":"2008","unstructured":"Wenning LA, Friedman EJ, Kost JT, Breidinger SA, Stek JE, Lasseter KC, et al. Lack of a significant drug interaction between raltegravir and tenofovir. Antimicrob Agents Chemother. 2008;52(9):3253\u20138. https:\/\/doi.org\/10.1128\/AAC.00005-08.","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"1031_CR60","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1093\/jac\/dkx507","volume":"73","author":"C Waitt","year":"2018","unstructured":"Waitt C, Olagunju A, Nakalema S, Kyohaire I, Owen A, Lamorde M, et al. Plasma and breast milk pharmacokinetics of emtricitabine, tenofovir and lamivudine using dried blood and breast milk spots in nursing African mother-infant pairs. J Antimicrob Chemother. 2018;73(4):1013\u20139. https:\/\/doi.org\/10.1093\/jac\/dkx507.","journal-title":"J Antimicrob Chemother"},{"issue":"10","key":"1031_CR61","doi-asserted-by":"publisher","first-page":"4086","DOI":"10.1128\/AAC.00419-09","volume":"53","author":"M Di Mascio","year":"2009","unstructured":"Di Mascio M, Srinivasula S, Bhattacharjee A, Cheng L, Martiniova L, Herscovitch P, et al. Antiretroviral tissue kinetics: in vivo imaging using positron emission tomography. Antimicrob Agents Chemother. 2009;53(10):4086\u201395. https:\/\/doi.org\/10.1128\/AAC.00419-09.","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"1031_CR62","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1097\/QAD.0000000000001004","volume":"30","author":"A Gagneux-Brunon","year":"2016","unstructured":"Gagneux-Brunon A, Botelho-Nevers E, Fresard A, Lucht F. Preventing long-term tenofovir renal toxicity by pharmacokinetic assessment. AIDS. 2016;30(4):665\u20136. https:\/\/doi.org\/10.1097\/QAD.0000000000001004.","journal-title":"AIDS"},{"key":"1031_CR63","doi-asserted-by":"publisher","first-page":"248","DOI":"10.3389\/fphar.2014.00248","volume":"5","author":"DM Moss","year":"2014","unstructured":"Moss DM, Neary M, Owen A. The role of drug transporters in the kidney: lessons from tenofovir. Front Pharmacol. 2014;5:248. https:\/\/doi.org\/10.3389\/fphar.2014.00248.","journal-title":"Front Pharmacol"},{"issue":"1","key":"1031_CR64","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1097\/QAD.0000000000000112","volume":"28","author":"Z Neumanova","year":"2014","unstructured":"Neumanova Z, Cerveny L, Ceckova M, Staud F. Interactions of tenofovir and tenofovir disoproxil fumarate with drug efflux transporters ABCB1, ABCG2, and ABCC2; role in transport across the placenta. AIDS. 2014;28(1):9\u201317. https:\/\/doi.org\/10.1097\/QAD.0000000000000112.","journal-title":"AIDS"},{"issue":"9","key":"1031_CR65","doi-asserted-by":"publisher","first-page":"e8728","DOI":"10.1002\/rcm.8728","volume":"34","author":"Z Ma","year":"2020","unstructured":"Ma Z, Li S, He D, Wang Y, Jiang H, Zhou H, et al. Rapid quantification of tenofovir in umbilical cord plasma and amniotic fluid in hepatitis B mono-infected pregnant women during labor by ultra-performance liquid chromatography\/tandem mass spectrometry. Rapid Commun Mass Spectrom. 2020;34(9):e8728. https:\/\/doi.org\/10.1002\/rcm.8728.","journal-title":"Rapid Commun Mass Spectrom"},{"issue":"8","key":"1031_CR66","doi-asserted-by":"publisher","first-page":"2660","DOI":"10.1021\/acs.molpharmaceut.7b00133","volume":"14","author":"M Swedrowska","year":"2017","unstructured":"Swedrowska M, Jamshidi S, Kumar A, Kelly C, Rahman KM, Forbes B. In silico and in vitro screening for P-Glycoprotein interaction with tenofovir, darunavir, and dapivirine: an antiretroviral drug combination for topical prevention of colorectal HIV transmission. Mol Pharm. 2017;14(8):2660\u20139. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.7b00133.","journal-title":"Mol Pharm"},{"issue":"3","key":"1031_CR67","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1097\/QAI.0000000000000172","volume":"66","author":"D Donnell","year":"2014","unstructured":"Donnell D, Baeten JM, Bumpus NN, Brantley J, Bangsberg DR, Haberer JE, et al. HIV protective efficacy and correlates of tenofovir blood concentrations in a clinical trial of PrEP for HIV prevention. J Acquir Immune Defic Syndr. 2014;66(3):340\u20138. https:\/\/doi.org\/10.1097\/QAI.0000000000000172.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"5","key":"1031_CR68","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1111\/bcp.12685","volume":"80","author":"MM De Sousa","year":"2015","unstructured":"De Sousa MM, Hirt D, Urien S, Valade E, Bouazza N, Foissac F, et al. Physiologically-based pharmacokinetic modeling of renally excreted antiretroviral drugs in pregnant women. Br J Clin Pharmacol. 2015;80(5):1031\u201341. https:\/\/doi.org\/10.1111\/bcp.12685.","journal-title":"Br J Clin Pharmacol"},{"key":"1031_CR69","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.ejps.2017.05.055","volume":"106","author":"K Ball","year":"2017","unstructured":"Ball K, Jamier T, Parmentier Y, Denizot C, Mallier A, Chenel M. Prediction of renal transporter-mediated drug-drug interactions for a drug which is an OAT substrate and inhibitor using PBPK modelling. Eur J Pharm Sci. 2017;106:122\u201332. https:\/\/doi.org\/10.1016\/j.ejps.2017.05.055.","journal-title":"Eur J Pharm Sci"},{"key":"1031_CR70","doi-asserted-by":"publisher","unstructured":"Moss DM, Domanico P, Watkins M, Park S, Randolph R, Wring S, et al. Simulating intestinal transporter and enzyme activity in a physiologically based pharmacokinetic model for tenofovir disoproxil fumarate. Antimicrob Agents Chemother. 2017;61(7). https:\/\/doi.org\/10.1128\/AAC.00105-17.","DOI":"10.1128\/AAC.00105-17"},{"issue":"14","key":"1031_CR71","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.2174\/1389200224666230130093314","volume":"23","author":"X Zhang","year":"2023","unstructured":"Zhang X, Luo T, Yang H, Ma WY, He Q, Xu M, et al. Physiologically-based pharmacokinetic modeling of tenofovir disoproxil fumarate in pregnant women. Curr Drug Metab. 2023;23(14):1115\u201323. https:\/\/doi.org\/10.2174\/1389200224666230130093314.","journal-title":"Curr Drug Metab"},{"issue":"9","key":"1031_CR72","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1124\/dmd.114.058099","volume":"42","author":"K Abduljalil","year":"2014","unstructured":"Abduljalil K, Cain T, Humphries H, Rostami-Hodjegan A. Deciding on success criteria for predictability of pharmacokinetic parameters from in vitro studies: an analysis based on in vivo observations. Drug Metab Dispos. 2014;42(9):1478\u201384. https:\/\/doi.org\/10.1124\/dmd.114.058099.","journal-title":"Drug Metab Dispos"}],"container-title":["The AAPS Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12248-025-01031-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1208\/s12248-025-01031-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12248-025-01031-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T17:57:27Z","timestamp":1740506247000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1208\/s12248-025-01031-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,12]]},"references-count":72,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,2]]}},"alternative-id":["1031"],"URL":"https:\/\/doi.org\/10.1208\/s12248-025-01031-y","relation":{},"ISSN":["1550-7416"],"issn-type":[{"value":"1550-7416","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,12]]},"assertion":[{"value":"12 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Institutional Review Board Statement"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed Consent Statement"}},{"value":"KA, MSD, and IG are full-time employees of Certara Predictive Technologies, UK and may hold shares in Certara. FS is a full-time employee of GSK and was a former employee of Certara, UK. SB has no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}}],"article-number":"43"}}